NCT Number |
Study Title |
Sponsor |
NCT03038776 |
Recombinant H7 Hemagglutinin Influenza Vaccine Trial |
Vaxine Pty Ltd |
NCT00530660 |
Safety and Immunogenicity Study of a Booster Vaccination With a Non-Adjuvanted H5N1 Influenza Vaccine (Follow Up to Study 810501) |
Ology Bioservices |
NCT02743676 |
A Retrospective, Observational Registry of Participants With Avian Influenza Infection |
Hoffmann-La Roche |
NCT04669691 |
A Dose-ranging Pediatric Study of an Adjuvanted Pandemic Influenza Vaccine |
Seqirus |
NCT03651544 |
The Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac |
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation |
NCT01142362 |
Study of VGX-3400X, H5N1 Avian Influenza Virus DNA Plasmid + Electroporation in Healthy Adults |
Inovio Pharmaceuticals |
NCT01107262 |
Avian Influenza Studies In Lebanon |
St. Jude Children’s Research Hospital |
NCT00311480 |
Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two(Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines in Non-Elderly Adult and Elderly Subjects |
Novartis |
NCT01258062 |
Study to Assess Safety of an Inactivated H5N1 Influenza Vaccine Administered in GelVac Nasal Powder to Healthy Young Adults |
Ology Bioservices |
NCT00417560 |
Inactivated Influenza A/H5N1 Vaccine in Adult Subjects at Risk of Occupational Exposure to Live H5N1 Viruses |
Centers for Disease Control and Prevention |
NCT03834376 |
Pre-Approval Access to Pimodivir for the Treatment of Patients With H7N9 Influenza A Infection |
Janssen Research & Development, LLC |
NCT03472976 |
H5N1 With or Without Topical Aldara in Healthy Adults |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT01184976 |
Study Of VGX-3400, H5N1 Avian Flu Virus Plasmid DNA With Electroporation Device In Healthy Adult Males |
GeneOne Life Science, Inc. |
NCT00900991 |
Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in Children |
Sinovac Biotech Co., Ltd |
NCT01698060 |
Immunogenicity of ND1.1 by Delivery Directly to the Ileum |
Vaxart |
NCT03755427 |
A Study of An Adjuvanted Inactivated H7N9 Influenza Vaccine |
Shanghai Institute Of Biological Products |
NCT00489931 |
Phase I Open-Label Study of Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for Influenza Virus H5 Hemagglutinin Protein Given Intradermally |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT00884182 |
Safety and Immunogenicity of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Children |
Sanofi Pasteur, a Sanofi Company |
NCT00841763 |
Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects |
Novartis |
NCT02078674 |
A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1 Adjuvant |
Novavax |
NCT00783926 |
Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant) |
Ology Bioservices |
NCT00640874 |
A Prospective Study to Examine the Effectiveness and Safety of Antivirals in Volunteers Who Receive Short-term Prophylaxis Against Pandemic Influenza |
Kirby Institute |
NCT03682120 |
Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59® Adjuvant to Prevent Avian Influenza |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT01594320 |
A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 1 |
Novavax |
NCT03745274 |
Two Doses of GHB04L1 for Pandemic Influenza Prophylaxis in Healthy Adults |
AVIR Green Hills Biotechnology AG |
NCT00439530 |
Pharmacologic Study of Oseltamivir in Healthy Volunteers |
Mahidol University |
NCT02839330 |
A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age |
Seqirus |
NCT00337896 |
T and B Cell Response to Avian Flu Vaccine |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT00439335 |
Higher Dose Intradermal H5 Vaccine |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT00516035 |
Single Group Study of the Safety of and Immune Response to a Bird Flu Vaccine (H7N3) in Healthy Adults |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT00478816 |
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults Unprimed and Primed With Adjuvanted or Non-adjuvanted Influenza Vaccines |
Novartis Vaccines |
NCT00537524 |
Immunogenicity, Safety and Tolerability of Two Doses of a Pre-pandemic Influenza Vaccine in Participants Aged 6 Months to 17 Years |
Novartis Vaccines |
NCT01044095 |
Study of Seasonal Influenza Vaccine Against H5N1 Avian Influenza Virus |
Armed Forces Research Institute of Medical Sciences, Thailand |
NCT01995695 |
Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy Adults |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT00347672 |
Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT00545701 |
Immunogenicity and Safety of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Adults |
Sanofi Pasteur, a Sanofi Company |
NCT01897701 |
A(H7N9) VLP Antigen Dose Ranging Study With Adjuvant 1 |
Novavax |
NCT00519389 |
Safety, Reactogenicity and Immunogenicity of an H5N1 VLP |
Novavax |
NCT02586792 |
H7N9 Boost in Healthy Adults |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT02095444 |
Using Human Menstrual Blood Cells to Treat Acute Lung Injury Caused by H7N9 Bird Flu Virus Infection |
S‑Evans Biosciences Co., Ltd. |
NCT01323946 |
Study to Evaluate the Immunogenicity and Safety of an Investigational Pandemic Influenza Vaccine in Children |
GlaxoSmithKline |
NCT00695669 |
A Trial to Test the Response to Different Vaccination Regimens With an H5N1 Vaccine With AS03 in Adults Aged 18–64 |
GlaxoSmithKline |
NCT00848029 |
Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects Using Four Different Vaccination Schedules |
Novartis Vaccines |
NCT00415129 |
Safety and Immunogenicity of an Intramuscular Pandemic Influenza Vaccine in Adults and the Elderly |
Sanofi Pasteur, a Sanofi Company |
NCT01382329 |
H5N1 Vaccine Study in Japanese Adults |
Ology Bioservices |
NCT00841646 |
Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects |
Novartis Vaccines |
NCT01573312 |
H5N1 Vaccination With and Without AS03: Systems Biology Analysis |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT00382980 |
Dose-Escalating Trial Using Vero Cell-culture Derived H5N1 +/- Aluminum in Adults |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT00488046 |
Single Group Study of the Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT00680069 |
H5N1 (Clade 2) Vaccination of Adults and Elderly |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT00240968 |
H5 Booster After a Two Dose Schedule |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT01640691 |
Immunogenicity and Safety of Pandemic Influenza Vaccine in Healthy Adults |
Adimmune Corporation |
NCT01236040 |
Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 – 49 Years Old |
GlaxoSmithKline |
NCT02719743 |
A Dose Ranging Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals’ GSK1557484A Vaccine in Children 6 to Less Than 36 Months of Age |
GlaxoSmithKline |
NCT00719043 |
Immunogenicity & Safety of GSK’s Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 Years |
GlaxoSmithKline |
NCT03739229 |
Reactogenicity, Safety and Immunogenicity of a LAIV А/17/Hong Kong/2017/75108 H7N9 Influenza Vaccine |
Research Institute of Influenza, Russia |
NCT01657929 |
H5-VLP + GLA-AF Vaccine Trial in Healthy Adult Volunteers |
Access to Advanced Health Institute (AAHI) |
NCT00532792 |
A/H5N1 Dose Ranging Study With Adjuvant Patch |
Intercell USA, Inc. |
NCT00895544 |
Immunogenicity and Safety Study of a Single Prime-Boost Vaccination Schedule With a H5N1 Influenza Vaccine in Adults |
Ology Bioservices |
NCT01942265 |
H7N9 Mix and Match With AS03 and MF59 in Healthy Adults |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT02480101 |
Reactogenicity, Safety and Immunogenicity of a LAIV H7N9 Influenza Vaccine |
Research Institute of Influenza, Russia |
NCT01147068 |
Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults |
Protein Sciences Corporation |
NCT01766921 |
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects |
Novartis Vaccines |
NCT02151344 |
Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying Intervals |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT03312231 |
Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT00311727 |
Cell-Mediated Immune Responses to Influenza A/H5N1 Vaccine |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT01086657 |
An Open-Label, Randomized Phase I Study in Healthy Adults of the Safety and Immunogenicity of Prime-Boost Intervals With Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc.) Administered Alone or Following Re… |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT03581903 |
A Study in Healthy Adults to Assess Priming With Antigenically Mismatched Live Attenuated A/H7N3 Influenza Virus Vaccine Followed by Inactivated A/H7N9 Influenza Virus Vaccine |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT00519064 |
Immunogenicity and Safety of an Adjuvanted Inactivated Subunit Influenza Vaccine to Those of a Non-adjuvanted Inactivated Subunit Influenza Vaccine, When Administered to Adults Affected by Chronic Diseases |
Novartis Vaccines |
NCT02206464 |
H7 Influenza Prime-Boost Regimens in Healthy Adults: Recombinant H7 DNA Plasmid Vaccine, VRC-FLUDNA071-00-VP, Administered Alone or With Monovalent Influenza Subunit Virion H7N9 Vaccine (MIV) as Prime With MIV Boost Compared to MIV Prime With MIV Boo… |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT03369808 |
A Clinical Trail Of An Adjuvanted Inactivated H7N9 Influenza Vaccine |
Shanghai Institute Of Biological Products |
NCT01195038 |
Immunogenicity and Safety Study of a Booster Vaccination With a Recombinant H5N1 Influenza HA Vaccine in Primed Adults |
UMN Pharma Inc. |
NCT00561184 |
Safety and Immunogenicity of a Booster Dose of ‑H5N1 Influenza Vaccine |
Novartis Vaccines |
NCT01675284 |
A Phase I Study to Evaluate the Safety, Reactogenicity, and Humoral Immune Responses to an Inactivated H5N1 Influenza Vaccine |
Medigen Biotechnology Corporation |
NCT00640302 |
A Prospective Study to Examine the Effectiveness and Safety of Neuraminidase Inhibitors in Index Cases With Presumed Pandemic Influenza |
Kirby Institute |
NCT02680002 |
Assess the Safety & Immunogenicity of Stored Inactivated Influenza H5N1 Virus Vaccine Given With & Without Stored MF59 Adjuvant |
Biomedical Advanced Research and Development Authority |
NCT01052402 |
Safety and Immunogenicity Study of a H5N1 Influenza Vaccine (Vero Cell-Derived, Whole Virus) in Healthy Infants, Children and Adolescents |
Ology Bioservices |
NCT00110279 |
Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study A) |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT02091908 |
Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Underlying Medical Conditions |
Seqirus |
NCT00230750 |
Inactivated Influenza A/H5N1 Vaccine in the Elderly |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT00853255 |
Group Study of the Safety of and Immune Response to a Single Dose of Bird Flu Vaccine (H7N3) in Healthy Adults |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT01403155 |
A Follow-On Study With an H5 Influenza Vaccine for Subjects Who Participated in Study FLU-001 |
Inovio Pharmaceuticals |
NCT00297050 |
Safety and Dose Study of Peramivir for Influenza Treatment |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT03345043 |
Safety, Tolerability, and Immunogenicity of VAL-339851 in Healthy Adult Subjects |
ModernaTX, Inc. |
NCT00755703 |
Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine. |
Altimmune, Inc. |
NCT01045564 |
Safety and Immunogenicity of Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure |
GlaxoSmithKline |
NCT00240903 |
Revaccination With Subunit Influenza A/Vietnam/1203/2004 (H5N1) Vaccine |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT02335164 |
A Phase 1 Study to Evaluate the Immunogenicity and Safety of a Pandemic Avian Influenza Vaccine in Adults |
Vaxine Pty Ltd |
NCT03014310 |
H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: Immunology |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT00711295 |
Phase 3 Study of a H5N1 Vaccine in Adults, Elderly and Specified Risk Groups |
Ology Bioservices |
NCT01250795 |
Safety and Immunogenicity Of A Recombinant H5N1 Vaccine In Adults |
Fraunhofer, Center for Molecular Biotechnology |
NCT01928472 |
Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years |
Novartis Vaccines |
NCT00908687 |
A/H5N1/LT Dose Ranging Study |
Intercell USA, Inc. |
NCT00298233 |
High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT00434733 |
Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects |
Novartis |
NCT00382187 |
Safety and Immunogenicity of Two Adjuvanted and One Non-adjuvanted H5N1 Influenza Vaccine in Adults |
Novartis Vaccines |
NCT00280033 |
H5 Adult – Chiron Study of Bird Flu Vaccine |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT00660257 |
Safety and Immunogenicity of Booster Dose of An Inactivated,Adjuvanted Whole-Virion Pandemic Influenza(H5N1)Vaccine |
Sinovac Biotech Co., Ltd |
NCT01086566 |
Cellular and Humoral Immune Response to Primary and Secondary Immunization With Subvirion H5N1 Vaccines |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT05422326 |
A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed |
Seqirus |
NCT00868218 |
Study of a Parenterally Administered H5N1 Influenza Vaccine in Healthy Adults |
Rebecca Cox |
NCT01074736 |
Host Genetic Susceptibility to Avian Influenza A/H5N1 |
South East Asia Infectious Disease Clinical Research Network |
NCT02295813 |
Safety and Pharmacokinetics Study of FBF001 |
Fab’entech |
NCT00694213 |
Pandemic Influenza Plasmid DNA Vaccines (Needle-Free) |
Vical |
NCT00311649 |
Open Label Evaluation of H5N1 Vaccine at Vaccine Manufacturing Facilities |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT01999842 |
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals’ Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age |
GlaxoSmithKline |
NCT01938742 |
H7N9 Mix and Match With MF59 in Healthy Adults |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT01443936 |
Experimental AD4-H5-VTN Vaccine in Healthy Volunteers |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT00402649 |
Open-Label Study of H5 Vaccine in Participants of Protocol 04–077 |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT02171819 |
Influenza A/H5N1 Vaccine Clinical Trial (IVACFLU‑A/H5N1) – Phase 1 |
Institute of Vaccines and Medical Biologicals, Vietnam |
NCT01511419 |
Safety Trial of Live Attenuated Influenza (H7N3) Vaccine |
PATH |
NCT00133536 |
A/H5N1 Vaccine in Healthy Children Aged 2–9 Years |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT00310206 |
H5N1 Vaccine Intramuscular Versus Intradermal in Healthy Adults |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT00294099 |
H5 Vaccine Alone or With Aluminum Hydroxide in Elderly Adults |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT00517517 |
Safety and Immunogenicity Study of Two Doses of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived) |
Ology Bioservices |
NCT00296634 |
H5 Vaccine Alone or With Adjuvant in Healthy Adults |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT02177734 |
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals’ Influenza Vaccine(s) GSK3277510A and GSK3277509A in Adults 18 to 60 Years of Age |
GlaxoSmithKline |
NCT01353534 |
Open-label Study to Assess Immunogenicity and Safety of a Vaccine Enhancement Patch When Administered With 2 Doses of H5N1 Vaccine |
Intercell USA, Inc. |
NCT01317758 |
H5N1 Mix and Match With AS03 |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT00912496 |
Booster Trial to 07–0019 With A/Anhui/05 With and Without MF59 |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT01596725 |
A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 2 |
Novavax |
NCT02691130 |
Assess the Safety and Immunogenicity of M‑001 as A Standalone Influenza Vaccine and as A H5N1 Vaccine Primer in Adults |
BiondVax Pharmaceuticals ltd. |
NCT02229357 |
Evaluation of Priming Effects by PLAI Vaccine on the Subsequent Response to Inactivated H5N1 Vaccine |
Mahidol University |
NCT01776541 |
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults |
Novartis Vaccines |
NCT01037634 |
Safety and Efficacy of Oseltamivir in Children Younger Than One Year of Age |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT01578317 |
Immune Responses to H5N1 Vaccine With and Without AS03 Adjuvant |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT00115986 |
A/H5N1in Adult – Aventis |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT01443663 |
Evaluating the Safety and Immune Response to an H5N1 Influenza Vaccine in People Who Have Previously Received an H5N1 or H7N3 Influenza Vaccine and in People Who Have Never Received a Live Attenuated Influenza Vaccine |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT00664417 |
Study of Different Formulations of an Intramuscular A/H5N1 Inactivated, Split Virion Influenza Adjuvanted Vaccine |
Sanofi |
NCT03738241 |
2017 A/H7N9 IIV Revaccination |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT02624219 |
H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT03283319 |
Panblok H7 Vaccine Adjuvanted With AS03 or MF59 |
Biomedical Advanced Research and Development Authority |
NCT00349141 |
Safety and Immunogenicity Study of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived) |
Ology Bioservices |
NCT01310413 |
Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age |
GlaxoSmithKline |
NCT00812019 |
Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18–40 Years Old) |
Seqirus |
NCT05397119 |
A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine in Healthy Adults |
BlueWillow Biologics |
NCT01298206 |
Case-control Study of Pandemic A/H1N1 Influenza Risk Factors In Lebanon |
St. Jude Children’s Research Hospital |
NCT01389466 |
Study to Evaluate the Safety and Immunogenicity of MG1109 in Healthy Adult Volunteers |
Green Cross Corporation |
NCT00481065 |
Immunogenicity, Safety and Tolerability of Prepandemic Influenza and Seasonal Influenza Vaccine in Adult Subjects |
Novartis |
NCT01379937 |
A Study to Evaluate the Safety and Immunogenicity of a Prime-boost Schedule of GSK Biologicals’ Influenza Vaccine in Children |
GlaxoSmithKline |
NCT01910519 |
Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without Adjuvant System 03 (AS03) |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT00814385 |
Immunogenicity of Adjuvanted or Non-adjuvanted H5N1 Booster Vaccine in Adults Primed to A/VN/1194/04 |
University Hospitals, Leicester |
NCT00491985 |
Safety and Immunogenicity of 2 Formulations of an Intramuscular A/H5N1 Pandemic Influenza Vaccine in Children |
Sanofi Pasteur, a Sanofi Company |
NCT00408109 |
Safety Study of Avian Flu Vaccine |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT00771615 |
Immunogenicity & Safety of GSK’s Avian Flu Vaccine 1557484A Given to Adults Aged 18–64 Years |
GlaxoSmithKline |
NCT01656356 |
Phase I Safety and Immunogenicity of Live Attenuated Influenza H5 Candidate Vaccine Strain A/17/Turkey/Turkey/05/133 (H5N2) in Healthy Thai Volunteers |
Mahidol University |
NCT02612909 |
A Safety and Immunogenicity Study of IVACFLU‑A/H5N1 |
Institute of Vaccines and Medical Biologicals, Vietnam |
NCT02107807 |
Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine |
Seqirus |
NCT00457509 |
Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy Adults |
Sanofi Pasteur, a Sanofi Company |
NCT00428753 |
China Case Control Avian Influenza |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT00703053 |
H5N1 Priming and Boosting Strategies |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT01317745 |
H5N1 Mix and Match With MF59 |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT01676675 |
A Phase I Clinical Trial With Whole Virus Inactivated Influenza H5N1 Vaccine in Healthy Adolescents and Adults |
Jiangsu Province Centers for Disease Control and Prevention |
NCT00397215 |
Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Adults Over 60 Years of Age |
GlaxoSmithKline |
NCT00620815 |
Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above |
Novartis Vaccines |
NCT00462215 |
Phase 3 Immunogenicity and Safety Study of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived) |
Ology Bioservices |
NCT01774032 |
H5N1 Vaccine Study in Japanese Elderly Population Aged 65 Years and Older |
Ology Bioservices |
NCT01150552 |
Studies of Avian Influenza Transmission to Humans in Egypt |
St. Jude Children’s Research Hospital |
NCT00709800 |
Pandemic Influenza Plasmid DNA Vaccines (Needle) |
Vical |
NCT01658800 |
Study of the Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18–49 |
VaxInnate Corporation |
NCT00734175 |
Safety of and Immune Response to Recombinant Live-Attenuated Influenza H6N1 Virus Vaccine Vaccine |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT00311675 |
St. Jude Open Label H5 Trial |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT00922259 |
Safety and Immunogenicity of Live Influenza A Vaccine for Avian Influenza H7N7 |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT03318315 |
Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4 |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT00380237 |
Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study B) |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT03330899 |
Safety and Immunogencity of H7N9 Influenza Antigen With 2 Adjuvant Formulations in Healthy Adults in Brazil |
Butantan Institute |
NCT03497845 |
Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59 |
Biomedical Advanced Research and Development Authority |
NCT02274545 |
Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years Old |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT01335347 |
Safety Study of an Oral Vaccine to Prevent Avian Influenza |
Vaxart |
NCT00309647 |
Study to Evaluate the Safety and Immunogenicity of Pandemic Monovalent (H5N1) Influenza Vaccines (Whole Virus Formulation) in Adults 18 and 60 Years of Age |
GlaxoSmithKline |
NCT00980447 |
Immunogenicity, Safety and Optimal Dose Finding Study of Recombinant Influenza H5N1 Vaccine in Healthy Young Adults |
UMN Pharma Inc. |
NCT00984945 |
Safety Study of a Plant-based H5 Virus-Like Particles (VLP) Vaccine in Healthy Adults |
Medicago |
NCT00356798 |
Randomized, Double Blinded, Placebo Control Clinical Trial of Pandemic Influenza Inactive Vaccine on Healthy Subjects |
Sinovac Biotech Co., Ltd |
NCT01006798 |
Safety and Immunogenicity of Replication-Competent Adenovirus 4‑vectored Vaccine for Avian Influenza H5N1 |
Emergent BioSolutions |
NCT00319098 |
Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged 18 Years and Above |
GlaxoSmithKline |
NCT01416571 |
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals’ Monovalent Pandemic H5N1 Vaccine in Adults |
GlaxoSmithKline |
NCT00428493 |
Prospective Study of AI H5N1 in China |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT02957656 |
Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT02153671 |
Immunogenicity of H5N1 Vaccine Following H5N2 |
PATH |
NCT00914771 |
Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 Influenza Vaccines Containing 2 Doses of H5N1 Influenza Antigen, in Non-elderly Adult and Elderly Subjects |
Novartis Vaccines |
NCT00383071 |
Development of Immune Globulin Treatment for Avian Flu |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT01560793 |
Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18–49 Years |
VaxInnate Corporation |
NCT01776554 |
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children |
Novartis Vaccines |
NCT04789577 |
A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals’ Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older |
GlaxoSmithKline |
NCT02213354 |
H7N9 Mix and Match With MF59 in Healthy Elderly Persons |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT03701061 |
Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response |
Emory University |
NCT02436928 |
A Study to Evaluate the Safety and Immunogenicity of H7N9 Influenza Vaccine (AT-501) in Healthy Adult Subjects |
Medigen Vaccine Biologics Corp. |
NCT03196661 |
Preliminary Study on Safety and Immunogenicity of Influenza A (H7N9) Vaccine in the Population |
Hualan Biological Bacterin Co. Ltd. |
NCT01788228 |
Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure |
GlaxoSmithKline |
NCT00640211 |
A Prospective Study to Examine the Effectiveness and Safety of Neuraminidase Inhibitors in Volunteers Who Receive Long-term Prophylaxis Against Pandemic Influenza: PIPET B |
Kirby Institute |
NCT03816878 |
Immunogenicity and Safety Study of Inactivated Subunit H5N1 Influenza Vaccine in Prior Recipients of Live Attenuated H2N2, H6N1 and H9N2 Influenza Vaccines and in H5N1 and Live Attenuated Vaccine Naïve Individuals |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT00776711 |
Vaccine for Prevention of Bird Flu |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT03589807 |
2013/2017 H7N9 Prime-Boost Interval |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT02251288 |
A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT00900588 |
Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in Adolescents |
Sinovac Biotech Co., Ltd |
NCT01987011 |
Phase III Study to Evaluate the Immunogenicity and Safety of MG1109 in Healthy Adult Volunteers |
Green Cross Corporation |
NCT02921997 |
H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses |
National Institute of Allergy and Infectious Diseases (NIAID) |
NCT01911754 |
Japanese Pediatric H5N1 Vaccine Study |
Ology Bioservices |